1.	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
2.	Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 30052004, NCT00196768
3.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
4.	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
5.	Acute Promyelocytic Leukemia 2006 (APL) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P050604, NCT00378365
6.	S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000572619, S0535, U10CA032102, SWOG-S0535, NCT00551460
7.	Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-040, NCT01404949
8.	Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 2010-0981, NCT01409161
9.	Study of Arsenic Trioxide in Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1988-11, NCT01470248
10.	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HEMAML0023, NCI-2013-00767, 26938, NCT01835288
11.	Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 11-107, NCT01397734
12.	Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) Phase: No phase specified Type: Treatment Status: Active Age: 1 to 16 Sponsor: Other Protocol IDs: CCAPL2010, NCT01191541
13.	Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: SKIN0015, NCI-2013-00387, NCT01791894